title: [Chronic heart failure : current guideline recommendations and innovations].
abstract: Chronic heart failure is one of the most common chronic diseases worldwide with increasing prevalence and incidence. Due to the high morbidity and mortality a standardized and evidence-based therapy is essential. The present article gives an overview of the innovations from 2014 based on the current guidelines of the European Society of Cardiology. First, improvements of established medication regimens regarding beta blockers, mineralocorticoid receptor antagonists and treatment options for heart rate reduction and disease management programs will be explained. Second, new pharmacological developments, such as the new substance class of angiotensin receptor blockers and neprilysin inhibitors (ARNI), will be presented. Finally, new insights into common comorbidities of chronic heart failure patients, such as atrial fibrillation and hyperkalemia will be discussed.
authors.affiliation: Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str., Geb. 40, 66421, Homburg/Saar, Deutschland, sebastian.ewen@uks.eu.
authors.forename: S
authors.initials: S
authors.lastname: Ewen
authors.forename: F
authors.initials: F
authors.lastname: Mahfoud
authors.forename: M
authors.initials: M
authors.lastname: Böhm
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage*; D002309:Cardiology / Q000592:standards*; D002316:Cardiotonic Agents / Q000008:administration & dosage; D002908:Chronic Disease; D005060:Europe; D019317:Evidence-Based Medicine; D005858:Germany; D006331:Heart Diseases / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage*; D015260:Neprilysin / Q000037:antagonists & inhibitors; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D002316:Cardiotonic Agents; D000451:Mineralocorticoid Receptor Antagonists; D015260:Neprilysin